The Brand Name BISPEC Has Generic Salt :: SOLIFENACIN 

BISPEC  Is From Company DR. REDDY’S Priced :: Rs. 275

BISPEC have SOLIFENACIN is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Overactive bladder

Drug Dose ::

Overactive bladder Adult: 5 mg once daily. If well tolerated, may increase to 10 mg once daily if needed. For patients who are concurrently taking CYP3A4 inhibitors (e.g. ketoconazole, ritonavir): Max dose: 5 mg once daily. Renal impairment: CrCl (ml/min) <30 Max: 5 mg daily. Hepatic impairment: Child-pugh class B: Max: 5 mg daily; Child-pugh class C: Use is not recommended. Contraindication ::

Uncontrolled narrow-angle glaucoma, urinary retention, gastric retention.

Drug Precautions ::

Increased risk of urinary retention in patients with bladder outflow obstruction. Caution in patients with decreased GI motility, GI obstructive diseases, controlled narrow-angle glaucoma, liver or kidney impairment, patients with known history of QT prolongation or other risk factors for QT prolongation. May cause drowsiness and/or blurred vision. Monitor serum creatinine clearance and liver function. Maintain adequate hydration. Increased susceptibility to heat prostration due to reduced ability to sweat. Pregnancy, lactation.

Drug Side Effects ::

Constipation, dyspepsia, nausea, upper abdominal pain, xerostomia, hypertension, oedema, headache, depression, fatigue, urinary tract infection, blurred vision, cough, influenza.

Pregnancy category ::

3

Drug Mode of Action ::  

Solifenacin is a selective M3 antimuscarinic that inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume and decreased detrusor muscle pressure.

Drug Interactions ::

May interfere with the prokinetic effects of cisapride and metoclopramide. Potentially Fatal: May reduce the stimulatory effect of secretin. Concurrent use with biperiden, orphenadrine, procyclidine or trihexyphenidyl may cause anticholinergic effects such as confusion and loss of bladder control; a washout period of 1 wk between using these drugs is recommended. May increase the ulcerogenic effect of potassium chloride. Strong CYP3A4 inhibitors (e.g. ketoconazole, fluconazole, itraconazole, erythromycin, telithromycin, clarithromycin, ritonavir, indinavir, nelfinavir, nefazodone, aprepitant, verapamil) may reduce the metabolism of solifenacin, thus increasing its plasma levels.